Arvoella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arvoella’s lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. Arvoella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. iNKT cells also contain an invariant T cell receptor (iTCR) that targets α-GalCer bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.
Arovella Therapeutics Limited (ASX:ALA)
Realising the Potential of Invariant Natural Killer T (iNKT) Cell Therapy
About Us
Arovella Therapeutics is a biotechnology company focused on leveraging its proprietary invariant Natural Killer T (iNKT) cell therapy platform from Imperial College London to address the treatment needs for both blood cancers and solid tumours.
Latest News
Company Overview
Board & Management
Dr Andrew Nash
Non-Executive Director
Dr Nash has over 35 years of practical drug development experience and executive leadership in the biotech and pharmaceutical sector. Dr Nash was CSO of CSL from 2020 until his retirement in March 2025 and is a Fellow of the Australian Academy of Science.
